Mineralys polishes $100M IPO plans ahead of phase 3 in hypertension

If we’re looking for good omens for biotech in 2023, then a planned $100 million IPO seems as good a sign as any. That’s how much Mineralys Therapeutics is currently aiming to bring in if the hypertension-focused biotech goes public as planned.